VBC Release Highlights
January 19, 2024
Practice Insights℠ is pleased to announce updates in the application to support the Merit-Based Incentive Payment System (MIPS).
MIPS Quality Measures Dashboard
The dashboard has been updated to reflect the below refinement(s) for:
| Measure | Description | |
|---|---|---|
|
MIPS #462: Bone Density Evaluation for Patients with Prostate Cancer and Receiving Androgen Deprivation Therapy |
This measure will now reflect the Benchmark File provided by CMS representing this measure as not having a benchmark for the year 2023. |
Practices will not notice a shift in the numerator or denominator. |
Status of Dashboard Updates for 2023
CMS releases updates to the quality measure specifications annually for the MIPS program. These measure specifications have been reviewed, and Practice Insights is working on the required technical updates to align with the revised requirements. McKesson will continue to notify practices once measures have been updated based on the current 2023 requirements. The measures listed below either have no 2023 update required or have been updated.
| Measure | Description |
|---|---|
MIPS Quality Measures Dashboard |
|
|
#047 |
Advance Care Plan |
|
#104 |
Adjuvant Hormonal Therapy for High-Risk or Very High-Risk Prostate Cancer |
|
#130 |
Current Medications Documentation |
|
#134 |
Preventive Care Screening: Screening for Depression and Follow-Up Plan |
|
#143 |
Pain Intensity Quantified |
|
#144 |
Pain Care Plan |
|
#226 |
Tobacco Screening and Cessation |
|
#236 |
Controlling High Blood Pressure |
|
#238 |
Use of High-Risk Meidcations in Older Adults |
|
#374 |
Closing the Referral Loop |
|
#450 |
Trastuzumab Received by Patients with AJCC Stage I (T1c), II and III and HER2+ Breast Cancer Receiving Adj Chemo |
|
#451 |
RAS (KRAS and NRAS) Gene Mutation Testing Performed for Patients with Metastatic Colorectal Cancer who Receive Anti-epidermal Growth Factor Receptor (EGFR) Monoclonal Antibody Therapy |
|
#452 |
Percentage of Adult Patients (aged 18 or older) with Metastatic Colorectal Cancer and RAS (KRAS & NRAS) Gene Mutation Spared Treatment with Anti-EGFR Monoclonal Antibodies |
|
#453 |
Percentage of Patients who Died from Cancer Receiving Systemic Cancer-Directed Therapy in the Last 147 Days of Life (Inverse Measure) |
|
#457 |
Patients Admitted to Hospice for < 3 Days |
|
#462 |
Bone Density Evaluation of Patients with Prostate Cancer and Receiving Androgen Deprivation Therapy |
|
PIMSH#1 |
Advance Care Planning in Stage 4 Disease |
|
PIMSH#2 |
Utilization of GCSF in Metastatic Colon/Rectal Cancer (Inverse Measure) |
|
PIMSH#4 |
Patient-Reported Pain Improvement |
|
PIMSH#8 |
Mutation Testing for Lung Cancer |
|
PIMSH#9 |
Supportive Care Drug Utilization in the Last 14 Days of Life (Inverse Measure) |
|
PIMSH#10 |
Hepatitis B Serology Testing for Prophylactic Treatment Prior to Receiving Anti CD20 Targeting Drugs |
|
PIMSH#15 |
Antiemetic Therapy for Low-and-Minimal-Emetic Risk Antineoplastic Agents in the Infusion Center-Avoidance of Overuse (Inverse Measure) |
|
PIMSH#16 |
Appropriate Antiemetic Therapy for High-and Moderate-Emetic-Risk Antineoplastic Agents in the Infusion Center |
